Skip to main content
. 2021 Dec 15;7(1):100311. doi: 10.1016/j.esmoop.2021.100311

Figure 2.

Figure 2

Efficacy of switch maintenance treatment with gatipotuzumab versus placebo.

Kaplan–Meier plots of (A) PFS based on irRECIST criteria (investigator assessment) and (B) OS. irRECIST, immune-related RECIST; OS, overall survival; PFS, progression-free survival.